MARTIN H MARKOWITZ

Summary

Affiliation: Aaron Diamond AIDS Research Center
Country: USA

Publications

  1. pmc Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Fl, New York, NY 10016, USA
    J Exp Med 200:761-70. 2004
  2. pmc Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection
    Teresa H Evering
    Aaron Diamond AIDS Research Center, New York, New York, USA
    PLoS Pathog 8:e1002506. 2012
  3. ncbi request reprint Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients
    Martin Markowitz
    The Aaron Diamond AIDS Research Center, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 39:257-64. 2005
  4. ncbi request reprint Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection
    Saurabh Mehandru
    Aaron Diamond AIDS Research Centre and the Rockefeller University, New York, NY 10016, USA
    Expert Opin Investig Drugs 12:1821-8. 2003
  5. ncbi request reprint Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    Lancet 365:1031-8. 2005
  6. ncbi request reprint Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 45:401-10. 2007
  7. pmc A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
    J Virol 77:5037-8. 2003
  8. ncbi request reprint Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
    J Infect Dis 186:634-43. 2002
  9. pmc The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection
    Martin Markowitz
    Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University, New York, New York, USA
    J Infect Dis 201:1298-302. 2010
  10. ncbi request reprint Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication
    Bharat Ramratnam
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    J Acquir Immune Defic Syndr 35:33-7. 2004

Research Grants

  1. The Transmission and Fitness of Drug Resistant HIV-1
    Martin Markowitz; Fiscal Year: 2007
  2. TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1
    Martin Markowitz; Fiscal Year: 2003
  3. The Transmission and Fitness of Drug Resistant HIV-1
    Martin Markowitz; Fiscal Year: 2009
  4. The Transmission and Fitness of Drug Resistant HIV-1
    MARTIN H MARKOWITZ; Fiscal Year: 2010
  5. The Transmission and Fitness of Drug Resistant HIV-1
    Martin Markowitz; Fiscal Year: 2009
  6. TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1
    Martin Markowitz; Fiscal Year: 2001
  7. Understanding and Altering the Virologic Setpoint
    Martin Markowitz; Fiscal Year: 2006
  8. TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1
    Martin Markowitz; Fiscal Year: 2004
  9. TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1
    Martin Markowitz; Fiscal Year: 2002
  10. The Transmission and Fitness of Drug Resistant HIV-1
    MARTIN H MARKOWITZ; Fiscal Year: 2011

Detail Information

Publications40

  1. pmc Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Fl, New York, NY 10016, USA
    J Exp Med 200:761-70. 2004
    ..Given the importance of the mucosal compartment in HIV-1 pathogenesis, further study to elucidate the significance of the changes observed here is critical...
  2. pmc Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection
    Teresa H Evering
    Aaron Diamond AIDS Research Center, New York, New York, USA
    PLoS Pathog 8:e1002506. 2012
    ....
  3. ncbi request reprint Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients
    Martin Markowitz
    The Aaron Diamond AIDS Research Center, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 39:257-64. 2005
    ..The ESS40013 study tested 4-drug induction followed by 3-drug maintenance as initial antiretroviral therapy (ART) to reduce HIV RNA rapidly and then to simplify to an effective yet more convenient and tolerable regimen...
  4. ncbi request reprint Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection
    Saurabh Mehandru
    Aaron Diamond AIDS Research Centre and the Rockefeller University, New York, NY 10016, USA
    Expert Opin Investig Drugs 12:1821-8. 2003
    ..TPV dosed twice-daily, in the range of 500 - 1250 mg and combined with 100 - 200 mg of RTV has been shown to substantially and durably reduce viral load in HIV-1-infected drug-naive and experienced patients...
  5. ncbi request reprint Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    Lancet 365:1031-8. 2005
    ..Here, we describe a patient in whom these two factors arose concomitantly and assess the effects...
  6. ncbi request reprint Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 45:401-10. 2007
    ....
  7. pmc A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
    J Virol 77:5037-8. 2003
    ..7 day, and the generation time of HIV-1 in vivo, approximately 2 days, confirming the dynamic nature of HIV-1 replication...
  8. ncbi request reprint Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
    J Infect Dis 186:634-43. 2002
    ....
  9. pmc The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection
    Martin Markowitz
    Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University, New York, New York, USA
    J Infect Dis 201:1298-302. 2010
    ..Adjunctive therapy with cyclosporine in this setting does not provide apparent virologic or immunologic benefit...
  10. ncbi request reprint Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication
    Bharat Ramratnam
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    J Acquir Immune Defic Syndr 35:33-7. 2004
    ..Additional studies are needed to understand the host- and pathogen-related determinants of incomplete pharmacologic control of HIV-1 replication...
  11. ncbi request reprint Determining the relative efficacy of highly active antiretroviral therapy
    Michael Louie
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, NY 10016, USA
    J Infect Dis 187:896-900. 2003
    ..Nevertheless, we believe that optimal treatment regimens for HIV-1 have yet to be identified and that continued research to achieve this goal is warranted...
  12. ncbi request reprint Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience
    Anita Shet
    Aaron Diamond AIDS Research Center an affiliate of the Rockefeller University, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 41:439-46. 2006
    ....
  13. pmc In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression
    Hiroshi Mohri
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 48:511-21. 2008
    ..In 2005, we reported a case of transmitted MDR HIV-1 infection associated with dual tropism and rapid clinical progression. Here we report the in vitro characterization of the virus isolates...
  14. pmc Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Ave, 7th Fl, New York, NY 10016, USA
    J Virol 81:599-612. 2007
    ..Subsequently, ongoing infection of susceptible CD4+ T cells, along with activation-induced cellular death and host cytotoxic cellular response, are responsible for the persistence of the lesion...
  15. pmc Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, United States of America
    PLoS Med 3:e484. 2006
    ..Reconstitution in the peripheral blood during therapy with highly active antiretroviral therapy (HAART) is well established. However, the extent of immune reconstitution in the GI tract is unknown...
  16. ncbi request reprint Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials
    Roy T Steigbigel
    State University of New York at Stony Brook, The Rockefeller University, New York, New York, USA
    Clin Infect Dis 50:605-12. 2010
    ....
  17. ncbi request reprint Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York 1016, USA
    AIDS 16:1511-9. 2002
    ..To assess temporal changes in prevalence of transmitted HIV-1 drug resistance in a homogeneous cohort of newly infected individuals...
  18. pmc Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy
    Xia Jin
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 1st Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 76:2206-16. 2002
    ..In summary, vaccination with vCP1452 and recombinant gp160 appears safe and immunogenic in newly HIV-1-infected patients on HAART...
  19. pmc Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course
    Nicole Prada
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 49:117-22. 2008
    ..Attenuated infection with failure of tenofovir as prophylaxis has been reported in animal models. Here, we report a case of HIV-1 infection despite intermittent use of fixed-dose combination tenofovir and emtricitabine (FTC)...
  20. ncbi request reprint Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection
    Sandhya Vasan
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    Int Immunol 19:943-51. 2007
    ..Finally, preservation of NKT cell function may be important in HIV-infected individuals, as NKT cells display an anti-HIV-1 activity in vitro, mediated by IFN-gamma secretion...
  21. ncbi request reprint Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals
    Michael Louie
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA
    AIDS 17:1151-6. 2003
    ..To assess the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy by following the initial rate of decline in plasma viral load, which is a measure of the efficacy of therapy in blocking viral replication...
  22. pmc Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine
    Sandhya Vasan
    Aaron Diamond AIDS Research Center, New York, New York, United States of America
    PLoS ONE 5:e8617. 2010
    ..Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective was to evaluate the safety and immunogenicity of ADVAX in human volunteers...
  23. ncbi request reprint Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY, USA
    J Acquir Immune Defic Syndr 46:125-33. 2007
    ..This study explored the antiretroviral activity and safety of raltegravir in treatment-naive patients with plasma HIV-1 RNA levels > or = 5000 copies/mL and CD4 T-cell counts > or = 100 cells/mm...
  24. pmc Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 81:11016-31. 2007
    ..Though safe, the use of MAbs generally delayed, but did not prevent, virologic rebound. Consideration should be given to further pilot studies with alternative combinations of MAbs and perhaps additional novel treatment modalities...
  25. ncbi request reprint The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy
    Jerome K Percus
    Courant Institute of Mathematical Sciences, New York University, New York, NY 10012, USA
    Bull Math Biol 65:263-77. 2003
    ....
  26. ncbi request reprint The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    J Allergy Clin Immunol 116:419-22. 2005
    ..Ongoing work in this field is likely to have a significant effect on HIV research in the near future...
  27. ncbi request reprint Predictors of response to highly active antiretroviral therapy
    Andrea Low
    Rockefeller University, New York, USA
    AIDS Read 16:425-8, 430-1, 434, 436. 2006
    ..The factors that are predictors of response to antiretroviral therapy, including adherence, stage of disease at baseline, treatment history, and demographic factors, are discussed...
  28. ncbi request reprint Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches
    Anita Shet
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, NY 10016, USA
    Curr Opin Investig Drugs 7:709-20. 2006
    ....
  29. pmc Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 77:7736-45. 2003
    ..Further studies are needed to elucidate the precise regions that are essential for these characteristics...
  30. ncbi request reprint Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1
    Teresa Hope Evering
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
    Drugs Today (Barc) 43:865-77. 2007
    ..S. Food and Drug Administration (FDA) for the treatment of HIV-1 as part of combination antiretroviral therapy in treatment-experienced patients-providing an additional option for the management of the HIV-1 infected individual...
  31. ncbi request reprint Raltegravir: an integrase inhibitor for HIV-1
    Teresa H Evering
    The Aaron Diamond AIDS Research Center Rockefeller University, 455 First Avenue, New York, NY 10016, USA
    Expert Opin Investig Drugs 17:413-22. 2008
    ..Raltegravir has been shown to specifically inhibit the essential, HIV-1-encoded, integrase enzyme. As a result, this agent represents a promising chemotherapeutic agent for the treatment of HIV/AIDS...
  32. ncbi request reprint Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
    Martin Markowitz
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    J Acquir Immune Defic Syndr 43:509-15. 2006
    ....
  33. pmc Evidence of dysregulation of dendritic cells in primary HIV infection
    Rachel Lubong Sabado
    New York University, School of Medicine, Cancer Institute, New York, NY, USA
    Blood 116:3839-52. 2010
    ..Taken together, our data demonstrate that despite the reduction in circulating DC numbers, those that remain in the blood display hyperfunctionality and implicates a possible role for DCs in promoting chronic immune activation...
  34. ncbi request reprint Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection
    Martin Markowitz
    Aaron Diamond AIDS Research Center, New York, NY, USA
    J Acquir Immune Defic Syndr 52:350-6. 2009
    ..The purpose of this study was to evaluate the safety and efficacy of raltegravir vs efavirenz-based antiretroviral therapy after 96 weeks in treatment-naive patients with HIV-1 infection...
  35. ncbi request reprint Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective
    Michael Louie
    Aaron Diamond AIDS Research Center, 455 First Ave, 7th Floor, New York, NY 10016, USA
    Antiviral Res 55:15-25. 2002
    ..In this article, we discuss the issues surrounding the initiation of HAART, and describe the virologic and immunologic milestones that may be achieved with effective antiretroviral therapy...
  36. pmc Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    J Virol 78:14039-42. 2004
    ..We propose that the induction of 4E10-like antibodies should be a priority in designing immunogens to prevent HIV-1 infection...
  37. pmc Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy
    Michael A Poles
    New York University School of Medicine Department of Medicine, New York, New York, USA
    J Virol 77:10456-67. 2003
    ....
  38. doi request reprint Colonization and subsequent skin and soft tissue infection due to methicillin-resistant Staphylococcus aureus in a cohort of otherwise healthy adults infected with HIV type 1
    Anita Shet
    Aaron Diamond AIDS Research Center, New York, New York, USA
    J Infect Dis 200:88-93. 2009
    ..Previous antibiotic use was the only statistically significant risk factor for MRSA carriage. These data highlight the fact that MRSA colonization and infection are important clinical issues among asymptomatic HIV-1-infected individuals...
  39. pmc Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors
    Andrea Low
    Aaron Diamond AIDS Research Center, an affiliate of the Rockefeller University, 455 First Avenue, New York, NY 10016, USA
    Antimicrob Agents Chemother 53:4275-82. 2009
    ..Most of the highly prevalent polymorphisms have little effect on InSTI susceptibility in the absence of specific primary mutations. Baseline testing for integrase susceptibility in InSTI-naïve patients is not currently warranted...
  40. pmc DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes
    Leonia Bozzacco
    Laboratories of Cellular Physiology and Immunology, Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 104:1289-94. 2007
    ..Because of the consistency in eliciting CD8+ T cell responses, these data support the testing of alphaDEC-205 fusion mAb as a protein-based vaccine...

Research Grants11

  1. The Transmission and Fitness of Drug Resistant HIV-1
    Martin Markowitz; Fiscal Year: 2007
    ....
  2. TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1
    Martin Markowitz; Fiscal Year: 2003
    ..Finally, to further understand the viral dynamics of multi-drug resistant viruses, in vivo interventional studies will be performed in individuals to deduce parameters of drug resistant virus replication in vivo. ..
  3. The Transmission and Fitness of Drug Resistant HIV-1
    Martin Markowitz; Fiscal Year: 2009
    ..abstract_text> ..
  4. The Transmission and Fitness of Drug Resistant HIV-1
    MARTIN H MARKOWITZ; Fiscal Year: 2010
    ..abstract_text> ..
  5. The Transmission and Fitness of Drug Resistant HIV-1
    Martin Markowitz; Fiscal Year: 2009
    ..abstract_text> ..
  6. TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1
    Martin Markowitz; Fiscal Year: 2001
    ..Finally, to further understand the viral dynamics of multi-drug resistant viruses, in vivo interventional studies will be performed in individuals to deduce parameters of drug resistant virus replication in vivo. ..
  7. Understanding and Altering the Virologic Setpoint
    Martin Markowitz; Fiscal Year: 2006
    ..abstract_text> ..
  8. TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1
    Martin Markowitz; Fiscal Year: 2004
    ..Finally, to further understand the viral dynamics of multi-drug resistant viruses, in vivo interventional studies will be performed in individuals to deduce parameters of drug resistant virus replication in vivo. ..
  9. TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1
    Martin Markowitz; Fiscal Year: 2002
    ..Finally, to further understand the viral dynamics of multi-drug resistant viruses, in vivo interventional studies will be performed in individuals to deduce parameters of drug resistant virus replication in vivo. ..
  10. The Transmission and Fitness of Drug Resistant HIV-1
    MARTIN H MARKOWITZ; Fiscal Year: 2011
    ..abstract_text> ..